Evotec SE

EVTA

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    4,766

Stocks News & Analysis

stocks

ASX listed gold miner under pressure due to lower production

Shares have dropped nearly 20% since lowering 2026 volume guidance.
stocks

3 ASX opportunities after earnings season

Uncovering key opportunities following February’s results.
stocks

Oracle earnings: Solid execution secures revenue target and mitigates investor concerns

We raise our fair value estimate for Oracle stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,819.409.30-0.11%
CAC 408,000.3664.390.81%
DAX 4023,735.05171.040.73%
Dow JONES (US)47,119.91173.500.37%
FTSE 10010,419.51101.820.99%
HKSE25,868.5434.520.13%
NASDAQ22,511.53137.350.61%
Nikkei 22553,700.3950.76-0.09%
NZX 50 Index13,182.2317.650.13%
S&P 5006,734.9235.540.53%
S&P/ASX 2008,614.304.40-0.05%
SSE Composite Index4,049.9134.88-0.85%

Market Movers